Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
Gallbladder cancer (GBC) is the most common malignant tumour of the biliary tract. It is also
the most aggressive cancer of the biliary tract with the shortest median survival from the
time of diagnosis. Currently, radical resection is the most effective strategy to potentially
cure GBC. Chemotherapy and radiotherapy have been employed as adjuvant and palliative
setting, however, the overall survival is still dismal. This study aim to evaluate the
addition of Everolimus in addition to standard of care in gallbladder cancer.